DEVELOPMENT OF AN INTERLEUKIN-11 SIGNALLING ANTAGONIST
Grant number: 1147621 | Funding period: 2018 - 2022
Interleukin (IL)-11 is a soluble signalling molecule that is associated with many types of cancer. We have recently discovered that IL-11 signalling is a novel and tractable therapeutic target for the treatment of colon cancer. The aims of this proposal are to understand the structural details of IL-11 signalling. We will use this information to develop new and improved therapeutics for colon cancer.
Related publications (4)
Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome
Yin-Huai Chen, Diane B Zastrow, Riley D Metcalfe, Lisa Gartner, Freia Krause, Craig J Morton, Shruti Marwaha, Laure Fresard, Yong Huang, Chunli Zhao, Colleen McCormack, David Bick, Elizabeth A Worthey, Christine M Eng, Jessica Gold, Stephen B Montgomery, Paul G Fisher, Euan A Ashley, Matthew T Wheeler, Michael W Parker
BACKGROUND: Biallelic variants in IL6ST, encoding GP130, cause a recessive form of hyper-IgE syndrome (HIES) characterized by high..
Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival
Qiutong Huang, Nicolas Jacquelot, Adele Preaudet, Soroor Hediyeh-zadeh, Fernando Souza-Fonseca-Guimaraes, Andrew NJ McKenzie, Philip M Hansbro, Melissa J Davis, Lisa A Mielke, Tracy L Putoczki, Gabrielle T Belz
Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adap..
The structure of the extracellular domains of human interleukin 11? receptor reveals mechanisms of cytokine engagement
Riley D Metcalfe, Kaheina Aizel, Courtney O Zlatic, Paul M Nguyen, Craig J Morton, Daisy Sio-Seng Lio, Heung-Chin Cheng, Renwick CJ Dobson, Michael W Parker, Paul R Gooley, Tracy L Putoczki, Michael DW Griffin
Interleukin (IL) 11 activates multiple intracellular signaling pathways by forming a complex with its cell surface α-receptor, IL-..